why choose us

First received: December 15, 2022

Clinical Trial: A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer

Study Status: Completed

Recruit Status: RECRUITING

Condition: Non-muscle-invasive Bladder Cancer

Study Type: INTERVENTIONAL


Official Title: A Phase 1/2a Study of STM-416 Administered Intraoperatively to Patients Undergoing Transurethral Resection of Bladder Tumor (TURBT) for Recurrent High-Grade Papillary Bladder Cancer

Brief Summary: This is a first-in-human (FIH), Phase 1/2a, multi center, open-label, single treatment, dose escalation and expansion study designed to determine the safety and tolerability of STM-416 in patients with bladder cancer.

Read more